[go: up one dir, main page]

WO2013019889A3 - Bovine polyclonal antibody specific for human tnf - Google Patents

Bovine polyclonal antibody specific for human tnf Download PDF

Info

Publication number
WO2013019889A3
WO2013019889A3 PCT/US2012/049207 US2012049207W WO2013019889A3 WO 2013019889 A3 WO2013019889 A3 WO 2013019889A3 US 2012049207 W US2012049207 W US 2012049207W WO 2013019889 A3 WO2013019889 A3 WO 2013019889A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyclonal antibody
antibody specific
human tnf
htnf
polyclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/049207
Other languages
French (fr)
Other versions
WO2013019889A2 (en
Inventor
Barbara S. Fox
Eileen F. Bostwick
Daniel E. Tracey
Lisa D. SCHLEHUBER
Michael S. QUESENBERRY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avaxia Biologics Inc
Original Assignee
Avaxia Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/026112 external-priority patent/WO2012141791A1/en
Priority to AU2012290104A priority Critical patent/AU2012290104A1/en
Priority to BR112014002133A priority patent/BR112014002133A2/en
Priority to EP12819810.8A priority patent/EP2739650A4/en
Priority to CA2843315A priority patent/CA2843315A1/en
Priority to JP2014524054A priority patent/JP2014527957A/en
Application filed by Avaxia Biologics Inc filed Critical Avaxia Biologics Inc
Priority to CN201280042088.2A priority patent/CN103917555A/en
Publication of WO2013019889A2 publication Critical patent/WO2013019889A2/en
Publication of WO2013019889A3 publication Critical patent/WO2013019889A3/en
Priority to IL230748A priority patent/IL230748A0/en
Anticipated expiration legal-status Critical
Priority to ZA2014/01987A priority patent/ZA201401987B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure provides a composition comprising polyclonal antibodies that specifically bind to human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized with hTNF or an immunogenic portion thereof. Further provided are the methods for antigenic specificity analysis of the anti-hTNF polyclonal antibodies.
PCT/US2012/049207 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human tnf Ceased WO2013019889A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201280042088.2A CN103917555A (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human TNF
BR112014002133A BR112014002133A2 (en) 2011-08-01 2012-08-01 human tnf-specific bovine polyclonal antibody
EP12819810.8A EP2739650A4 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human tnf
CA2843315A CA2843315A1 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human tnf
JP2014524054A JP2014527957A (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human TNF
AU2012290104A AU2012290104A1 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human TNF
IL230748A IL230748A0 (en) 2011-08-01 2014-01-30 Bovine polyclonal antibody specific for human tnf
ZA2014/01987A ZA201401987B (en) 2011-08-01 2014-02-27 Bovine polyclonal antibody specific for human tnf

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513872P 2011-08-01 2011-08-01
US61/513,872 2011-08-01
PCT/US2012/026112 WO2012141791A1 (en) 2011-02-22 2012-02-22 Polyclonal antibody compositions
USPCT/US2012/026112 2012-02-22
US13/402,527 2012-02-22
US13/402,527 US20120213796A1 (en) 2011-02-22 2012-02-22 Polyclonal antibody compositions

Publications (2)

Publication Number Publication Date
WO2013019889A2 WO2013019889A2 (en) 2013-02-07
WO2013019889A3 true WO2013019889A3 (en) 2013-03-28

Family

ID=47629904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049207 Ceased WO2013019889A2 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human tnf

Country Status (9)

Country Link
EP (1) EP2739650A4 (en)
JP (1) JP2014527957A (en)
CN (1) CN103917555A (en)
AU (1) AU2012290104A1 (en)
BR (1) BR112014002133A2 (en)
CA (1) CA2843315A1 (en)
IL (1) IL230748A0 (en)
WO (1) WO2013019889A2 (en)
ZA (1) ZA201401987B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012243284A1 (en) * 2011-02-22 2013-09-12 Avaxia Biologics, Inc. Polyclonal antibody compositions
EP3359190A4 (en) * 2015-10-05 2020-05-06 Circle33 LLC ANTIBODIES WITH IMPROVED STABILITY ABOUT DIGESTION
GB201701404D0 (en) 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
GB201812262D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating proctitis
GB201812261D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating oral mucositis
WO2022103871A1 (en) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Therapeutic compositions for the treatment of covid-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106372A1 (en) * 1991-03-18 2002-08-08 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20080193473A1 (en) * 2005-05-24 2008-08-14 Neovacs Method for Preparing a Stable Immunogenic Product Comprising Antigenic Heterocomplexes of Tnf Alpha and a Carrier Protein
US20100040604A1 (en) * 1996-02-09 2010-02-18 Salfeld Jochen G HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
US20100266607A1 (en) * 2007-10-02 2010-10-21 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199067I2 (en) * 1991-03-18 2006-03-16 Univ New York Human Tumor Necrosis Factor Specific Monoclonal and Chimeric Antibodies
WO2011017514A1 (en) * 2009-08-07 2011-02-10 Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
PL2488202T3 (en) * 2009-10-15 2015-12-31 Avaxia Biologics Inc Antibody therapeutics with local activity in the digestive tract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106372A1 (en) * 1991-03-18 2002-08-08 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20100040604A1 (en) * 1996-02-09 2010-02-18 Salfeld Jochen G HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
US20080193473A1 (en) * 2005-05-24 2008-08-14 Neovacs Method for Preparing a Stable Immunogenic Product Comprising Antigenic Heterocomplexes of Tnf Alpha and a Carrier Protein
US20100266607A1 (en) * 2007-10-02 2010-10-21 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYCULTBIOTECH: "MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR ALPHA (TNF-alpha) clone 5N.", TECHNICAL DATASHEET, 27 October 2009 (2009-10-27), XP055143532, Retrieved from the Internet <URL:http://www.hycultbiotech.com/doc4371.dx> [retrieved on 20121011] *

Also Published As

Publication number Publication date
CN103917555A (en) 2014-07-09
AU2012290104A1 (en) 2014-02-13
EP2739650A4 (en) 2015-04-01
WO2013019889A2 (en) 2013-02-07
EP2739650A2 (en) 2014-06-11
BR112014002133A2 (en) 2017-02-21
IL230748A0 (en) 2014-03-31
CA2843315A1 (en) 2013-02-07
ZA201401987B (en) 2017-03-27
JP2014527957A (en) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2013043933A3 (en) Cd27l antigen binding proteins
MX359384B (en) Improved assembly of bispecific antibodies.
WO2013173761A3 (en) St2 antigen binding proteins
ZA201703241B (en) Anti-c5 antibodies and methods of use
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
EP4342529A3 (en) Anti-c5 antibodies and methods of use
EA030777B9 (en) Anti-alpha synuclein binding molecules
WO2013019889A3 (en) Bovine polyclonal antibody specific for human tnf
MX354243B (en) Antibody polypeptides that antagonize cd40.
EP3786183A3 (en) Antigen binding constructs to cd3
WO2011127412A3 (en) Soluble human st-2 antibodies and assays
IN2014CN03936A (en)
MX341309B (en) Anti-il-23 heterodimer specific antibodies.
HK1198832A1 (en) Fn14 binding proteins and uses thereof
MX2013011706A (en) Novel egfr binding proteins.
PH12018502354B1 (en) Anti-c5 antibodies and methods of use
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
MX2015003150A (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
EA201500502A1 (en) Binding HER3 ANTIGEN PROTEINS CONNECTING BETA HER3 BAT
WO2012051282A3 (en) Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
MX2016014726A (en) Her1 antigen binding proteins binding to the beta-hairpin of her1.
WO2016029013A3 (en) Methods for improving immunological response in vaccinated animals
TH169581A (en) Protein binding to ST2 antigens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819810

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014524054

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2843315

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012290104

Country of ref document: AU

Date of ref document: 20120801

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012819810

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819810

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014002133

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014002133

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140128